Figure 1From: Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survivalKaplan-Meier Survival curves for (A) DFS (χ2 = 5.802, df1, p = 0.016) and (B) OS (χ2 = 3.639, df1, p = 0.056) at a median follow-up period of 4 years and 3 months (Log Rank [Mantel-Cox]).Back to article page